FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809434754> ?p ?o ?g. }

• W2809434754 abstract "Background: Delay in the intensification of type 2 diabetes (T2DM) treatment after metformin monotherapy failure, or clinical inertia, is often observed among patients with poor glycemic control. Sitagliptin is used frequently as an add-on to metformin monotherapy among patients with T2DM. The objective of the study is to evaluate the association between early treatment intensification with sitagliptin and glycemic goal attainment among patients failing metformin monotherapy. Methods: This retrospective database study of adult T2DM patients was conducted using the Quintiles Electronic Medical Record (EMR) database. The study population consisted of patients diagnosed with T2DM who failed to achieve A1c level of &lt;7% on metformin monotherapy between January 20and June 2015. The study included two groups (1) those who did not receive treatment intensification within 3 months after metformin failure (non-early group), but were intensified with any oral anti-hyperglycemic agent between 4 and 12 months and (2) those who were intensified with sitagliptin within 3 months (early sitagliptin group). A Cox regression analysis was conducted to evaluate the association between sitagliptin use and A1c goal attainment within 12 months. Results: We identified 2,852 patients aged ≥18 years with T2DM who failed metformin monotherapy, of which 362 patients were intensified with sitagliptin within 3 months and 2,490 patients were included in the non-early group. A multivariate Cox regression model adjusted for age, gender, BMI, smoking status, baseline A1c, comorbidities, and other nondiabetic medications showed that early sitagliptin therapy resulted in doubling the likelihood of achieving A1c goal attainment (HR 2.12; 95% CI 1.80-2.50) within 12 months compared to non-early group. Conclusion: Early intensification with sitagliptin results in higher goal achievement levels among patients failing metformin monotherapy failure. Disclosure F. Ejzykowicz: Employee; Self; Merck Sharp & Dohme Corp. J. Liu: Employee; Self; Merck & Co., Inc.. Employee; Spouse/Partner; Anthem, Inc.. Employee; Self; Janssen Scientific Affairs, LLC. S.S. Engel: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc. S. Rajpathak: Employee; Self; Merck & Co., Inc.." @default.
• W2809434754 created "2018-06-29" @default.
• W2809434754 creator A5030762710 @default.
• W2809434754 creator A5031476174 @default.
• W2809434754 creator A5033266357 @default.
• W2809434754 creator A5091743333 @default.
• W2809434754 date "2018-07-01" @default.
• W2809434754 modified "2023-09-25" @default.
• W2809434754 title "Impact of Early Intensification with Sitagliptin on Glycemic Goal Attainment among Patients with Metformin Monotherapy Failure" @default.
• W2809434754 doi "https://doi.org/10.2337/db18-1641-p" @default.
• W2809434754 hasPublicationYear "2018" @default.
• W2809434754 type Work @default.
• W2809434754 sameAs 2809434754 @default.
• W2809434754 citedByCount "0" @default.
• W2809434754 crossrefType "journal-article" @default.
• W2809434754 hasAuthorship W2809434754A5030762710 @default.
• W2809434754 hasAuthorship W2809434754A5031476174 @default.
• W2809434754 hasAuthorship W2809434754A5033266357 @default.
• W2809434754 hasAuthorship W2809434754A5091743333 @default.
• W2809434754 hasConcept C126322002 @default.
• W2809434754 hasConcept C134018914 @default.
• W2809434754 hasConcept C2777180221 @default.
• W2809434754 hasConcept C2778763485 @default.
• W2809434754 hasConcept C2779284873 @default.
• W2809434754 hasConcept C2779306644 @default.
• W2809434754 hasConcept C2780323712 @default.
• W2809434754 hasConcept C2780473172 @default.
• W2809434754 hasConcept C2908647359 @default.
• W2809434754 hasConcept C50382708 @default.
• W2809434754 hasConcept C555293320 @default.
• W2809434754 hasConcept C71924100 @default.
• W2809434754 hasConcept C99454951 @default.
• W2809434754 hasConceptScore W2809434754C126322002 @default.
• W2809434754 hasConceptScore W2809434754C134018914 @default.
• W2809434754 hasConceptScore W2809434754C2777180221 @default.
• W2809434754 hasConceptScore W2809434754C2778763485 @default.
• W2809434754 hasConceptScore W2809434754C2779284873 @default.
• W2809434754 hasConceptScore W2809434754C2779306644 @default.
• W2809434754 hasConceptScore W2809434754C2780323712 @default.
• W2809434754 hasConceptScore W2809434754C2780473172 @default.
• W2809434754 hasConceptScore W2809434754C2908647359 @default.
• W2809434754 hasConceptScore W2809434754C50382708 @default.
• W2809434754 hasConceptScore W2809434754C555293320 @default.
• W2809434754 hasConceptScore W2809434754C71924100 @default.
• W2809434754 hasConceptScore W2809434754C99454951 @default.
• W2809434754 hasIssue "Supplement_1" @default.
• W2809434754 hasLocation W28094347541 @default.
• W2809434754 hasOpenAccess W2809434754 @default.
• W2809434754 hasPrimaryLocation W28094347541 @default.
• W2809434754 hasRelatedWork W1546635462 @default.
• W2809434754 hasRelatedWork W2097893376 @default.
• W2809434754 hasRelatedWork W2099092932 @default.
• W2809434754 hasRelatedWork W2170003639 @default.
• W2809434754 hasRelatedWork W2301714968 @default.
• W2809434754 hasRelatedWork W2323077932 @default.
• W2809434754 hasRelatedWork W2325963726 @default.
• W2809434754 hasRelatedWork W3044322745 @default.
• W2809434754 hasRelatedWork W3139367797 @default.
• W2809434754 hasRelatedWork W2496840989 @default.
• W2809434754 hasVolume "67" @default.
• W2809434754 isParatext "false" @default.
• W2809434754 isRetracted "false" @default.
• W2809434754 magId "2809434754" @default.
• W2809434754 workType "article" @default.